Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update ... company incurred in Q3 ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

We recently published a list of 10 Stocks To Buy Before They Split Next. In this article, we are going to take a look at ...

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Given its strong performance, investors may be wondering if the stock is still a buy. Let's take a closer look to help decide. While Eli Lilly has a portfolio of drugs that help address several ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...